N -3 Fatty acids and risk for fatal coronary disease

William Harris, Francis B. Zotor

Research output: Contribution to journalArticle

Abstract

The purpose of this review is to consider the effects of the long-chain n-3 fatty acids found in marine foods, EPA and DHA, on risk for CVD, particularly fatal outcomes. It will examine both epidemiological and randomised controlled trial findings. The former studies usually examine associations between the dietary intake or the blood levels of EPA + DHA and CVD outcomes or, on occasion, total mortality. For example, our studies in the Framingham Heart Study and in the Women's Health Initiative Memory Study have demonstrated significant inverse relations between erythrocyte EPA + DHA levels (i.e. the Omega-3 Index) and total mortality. Recent data from the Cardiovascular Health Study reported the same relations between plasma phospholipid n-3 levels and overall healthy ageing. As regards randomised trials, studies in the 1990s and early 2000s were generally supportive of a cardiovascular benefit for fish oils (which contain EPA + DHA), but later trials were generally not able to duplicate these findings, at least for total CVD events. However, when restricted to effects on risk for fatal events, meta-analyses have shown consistent benefits for n-3 treatment. Taken together, the evidence is strong for a cardioprotective effect of EPA + DHA, especially when consumed in sufficient amounts to raise blood levels into healthy ranges. Establishing target EPA + DHA intakes to reduce risk for cardiovascular death is a high priority.

Original languageEnglish (US)
JournalProceedings of the Nutrition Society
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Omega-3 Fatty Acids
Coronary Disease
Fatal Outcome
Mortality
Fish Oils
Women's Health
Meta-Analysis
Phospholipids
Randomized Controlled Trials
Erythrocytes
Food
Health

Keywords

  • Biomarkers
  • Controlled clinical trials
  • CVD
  • DHA
  • EPA
  • Epidemiology
  • Fish oil
  • Mortality

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

N -3 Fatty acids and risk for fatal coronary disease. / Harris, William; Zotor, Francis B.

In: Proceedings of the Nutrition Society, 01.01.2019.

Research output: Contribution to journalArticle

@article{5d0ed46b94134cd89151a1a0f679be6d,
title = "N -3 Fatty acids and risk for fatal coronary disease",
abstract = "The purpose of this review is to consider the effects of the long-chain n-3 fatty acids found in marine foods, EPA and DHA, on risk for CVD, particularly fatal outcomes. It will examine both epidemiological and randomised controlled trial findings. The former studies usually examine associations between the dietary intake or the blood levels of EPA + DHA and CVD outcomes or, on occasion, total mortality. For example, our studies in the Framingham Heart Study and in the Women's Health Initiative Memory Study have demonstrated significant inverse relations between erythrocyte EPA + DHA levels (i.e. the Omega-3 Index) and total mortality. Recent data from the Cardiovascular Health Study reported the same relations between plasma phospholipid n-3 levels and overall healthy ageing. As regards randomised trials, studies in the 1990s and early 2000s were generally supportive of a cardiovascular benefit for fish oils (which contain EPA + DHA), but later trials were generally not able to duplicate these findings, at least for total CVD events. However, when restricted to effects on risk for fatal events, meta-analyses have shown consistent benefits for n-3 treatment. Taken together, the evidence is strong for a cardioprotective effect of EPA + DHA, especially when consumed in sufficient amounts to raise blood levels into healthy ranges. Establishing target EPA + DHA intakes to reduce risk for cardiovascular death is a high priority.",
keywords = "Biomarkers, Controlled clinical trials, CVD, DHA, EPA, Epidemiology, Fish oil, Mortality",
author = "William Harris and Zotor, {Francis B.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1017/S0029665118002902",
language = "English (US)",
journal = "Proceedings of the Nutrition Society",
issn = "0029-6651",
publisher = "Cambridge University Press",

}

TY - JOUR

T1 - N -3 Fatty acids and risk for fatal coronary disease

AU - Harris, William

AU - Zotor, Francis B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The purpose of this review is to consider the effects of the long-chain n-3 fatty acids found in marine foods, EPA and DHA, on risk for CVD, particularly fatal outcomes. It will examine both epidemiological and randomised controlled trial findings. The former studies usually examine associations between the dietary intake or the blood levels of EPA + DHA and CVD outcomes or, on occasion, total mortality. For example, our studies in the Framingham Heart Study and in the Women's Health Initiative Memory Study have demonstrated significant inverse relations between erythrocyte EPA + DHA levels (i.e. the Omega-3 Index) and total mortality. Recent data from the Cardiovascular Health Study reported the same relations between plasma phospholipid n-3 levels and overall healthy ageing. As regards randomised trials, studies in the 1990s and early 2000s were generally supportive of a cardiovascular benefit for fish oils (which contain EPA + DHA), but later trials were generally not able to duplicate these findings, at least for total CVD events. However, when restricted to effects on risk for fatal events, meta-analyses have shown consistent benefits for n-3 treatment. Taken together, the evidence is strong for a cardioprotective effect of EPA + DHA, especially when consumed in sufficient amounts to raise blood levels into healthy ranges. Establishing target EPA + DHA intakes to reduce risk for cardiovascular death is a high priority.

AB - The purpose of this review is to consider the effects of the long-chain n-3 fatty acids found in marine foods, EPA and DHA, on risk for CVD, particularly fatal outcomes. It will examine both epidemiological and randomised controlled trial findings. The former studies usually examine associations between the dietary intake or the blood levels of EPA + DHA and CVD outcomes or, on occasion, total mortality. For example, our studies in the Framingham Heart Study and in the Women's Health Initiative Memory Study have demonstrated significant inverse relations between erythrocyte EPA + DHA levels (i.e. the Omega-3 Index) and total mortality. Recent data from the Cardiovascular Health Study reported the same relations between plasma phospholipid n-3 levels and overall healthy ageing. As regards randomised trials, studies in the 1990s and early 2000s were generally supportive of a cardiovascular benefit for fish oils (which contain EPA + DHA), but later trials were generally not able to duplicate these findings, at least for total CVD events. However, when restricted to effects on risk for fatal events, meta-analyses have shown consistent benefits for n-3 treatment. Taken together, the evidence is strong for a cardioprotective effect of EPA + DHA, especially when consumed in sufficient amounts to raise blood levels into healthy ranges. Establishing target EPA + DHA intakes to reduce risk for cardiovascular death is a high priority.

KW - Biomarkers

KW - Controlled clinical trials

KW - CVD

KW - DHA

KW - EPA

KW - Epidemiology

KW - Fish oil

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=85062663392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062663392&partnerID=8YFLogxK

U2 - 10.1017/S0029665118002902

DO - 10.1017/S0029665118002902

M3 - Article

AN - SCOPUS:85062663392

JO - Proceedings of the Nutrition Society

JF - Proceedings of the Nutrition Society

SN - 0029-6651

ER -